Do you constrain heterogeneity or hotspots when delivering spine SBRT for bone metastases?

We treat bone and spine mets "SRS" style which means accepting high hot spots (130%) within the GTV to allow for steeper dose fall offs just outside the target and hence lower normal tissue doses...